ATE339960T1 - Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen - Google Patents
Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungenInfo
- Publication number
- ATE339960T1 ATE339960T1 AT00911684T AT00911684T ATE339960T1 AT E339960 T1 ATE339960 T1 AT E339960T1 AT 00911684 T AT00911684 T AT 00911684T AT 00911684 T AT00911684 T AT 00911684T AT E339960 T1 ATE339960 T1 AT E339960T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor
- agents
- cldc
- radiation
- treatment
- Prior art date
Links
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 239000002534 radiation-sensitizing agent Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 11
- 239000003795 chemical substances by application Substances 0.000 abstract 8
- 230000005855 radiation Effects 0.000 abstract 6
- NGGRGTWYSXYVDK-UHFFFAOYSA-N NSC 371331 Natural products C1=C(Cl)C(N)=NC(=O)N1C1OC(CO)C(O)C1 NGGRGTWYSXYVDK-UHFFFAOYSA-N 0.000 abstract 5
- 229940123974 Cytidine deaminase inhibitor Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- UCKYOOZPSJFJIZ-FMDGEEDCSA-N (4r)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 UCKYOOZPSJFJIZ-FMDGEEDCSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000637 radiosensitizating effect Effects 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Light Receiving Elements (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12247999P | 1999-03-01 | 1999-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339960T1 true ATE339960T1 (de) | 2006-10-15 |
Family
ID=22402946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00911684T ATE339960T1 (de) | 1999-03-01 | 2000-03-01 | Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1156827B1 (de) |
| AT (1) | ATE339960T1 (de) |
| AU (1) | AU3354500A (de) |
| CY (1) | CY1106296T1 (de) |
| DE (1) | DE60030842T2 (de) |
| DK (1) | DK1156827T3 (de) |
| ES (1) | ES2273672T3 (de) |
| PT (1) | PT1156827E (de) |
| WO (1) | WO2000051639A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003267309A1 (en) | 2000-11-16 | 2004-04-08 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
| AU2001297657A1 (en) * | 2000-11-16 | 2002-09-12 | Microspherix Llc | Polymeric imagable brachytherapy seed |
| US6746661B2 (en) | 2000-11-16 | 2004-06-08 | Microspherix Llc | Brachytherapy seed |
| CA2454147C (en) * | 2001-07-31 | 2013-05-21 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Inhibitor of dna methylation |
| AU2008200601B2 (en) * | 2001-07-31 | 2010-08-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA Methylation |
| US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| SE0301087D0 (sv) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
| JP5064025B2 (ja) | 2003-04-14 | 2012-10-31 | キシンテラ、アクチボラグ | インテグリンα１０β１を結合することができる新規モノクローナル抗体 |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| JP5687687B2 (ja) | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体 |
| UY32546A (es) | 2009-04-06 | 2010-10-29 | Eisai Inc | Composiciones y metodos para tratar cancer |
| AU2010234562B2 (en) | 2009-04-06 | 2016-05-12 | Taiho Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| US20140274757A1 (en) | 2013-03-14 | 2014-09-18 | Marie K. Kirby | Differential Methylation Level of CpG Loci That Are Determinative of a Biochemical Reoccurrence of Prostate Cancer |
| DK3383406T3 (da) | 2015-12-03 | 2022-01-10 | Epidestiny Inc | Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf |
| GB2580963C (en) * | 2019-02-01 | 2025-09-03 | Hemispherian As | Cancer therapies |
| CN110982832B (zh) * | 2019-11-12 | 2021-09-24 | 北京理工大学 | 一种辐射生物剂量计、制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0160079B1 (de) * | 1983-10-26 | 1990-01-31 | GREER, Sheldon B. | Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung |
| AU5300396A (en) * | 1995-03-01 | 1996-09-18 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
-
2000
- 2000-03-01 AT AT00911684T patent/ATE339960T1/de active
- 2000-03-01 ES ES00911684T patent/ES2273672T3/es not_active Expired - Lifetime
- 2000-03-01 WO PCT/US2000/002530 patent/WO2000051639A2/en not_active Ceased
- 2000-03-01 DK DK00911684T patent/DK1156827T3/da active
- 2000-03-01 DE DE60030842T patent/DE60030842T2/de not_active Expired - Lifetime
- 2000-03-01 PT PT00911684T patent/PT1156827E/pt unknown
- 2000-03-01 AU AU33545/00A patent/AU3354500A/en not_active Abandoned
- 2000-03-01 EP EP00911684A patent/EP1156827B1/de not_active Expired - Lifetime
-
2006
- 2006-12-20 CY CY20061101822T patent/CY1106296T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000051639A9 (en) | 2001-10-25 |
| ES2273672T3 (es) | 2007-05-16 |
| DK1156827T3 (da) | 2007-02-05 |
| DE60030842T2 (de) | 2007-05-10 |
| AU3354500A (en) | 2000-09-21 |
| CY1106296T1 (el) | 2011-10-12 |
| WO2000051639A3 (en) | 2001-01-11 |
| PT1156827E (pt) | 2007-01-31 |
| EP1156827B1 (de) | 2006-09-20 |
| WO2000051639A2 (en) | 2000-09-08 |
| DE60030842D1 (de) | 2006-11-02 |
| EP1156827A2 (de) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE339960T1 (de) | Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen | |
| Nandini et al. | Novel therapies in the management of oral cancer: An update | |
| Abbruzzese | New applications of gemcitabine and future directions in the management of pancreatic cancer | |
| Overgaard | Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue | |
| SE9704549D0 (sv) | Drug delivery system | |
| Leonetti et al. | Efficacy of a nitric oxide–releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts | |
| Takai et al. | Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer | |
| US20040192639A1 (en) | Dramatic simplification of a method to treat neoplastic disease by radiation | |
| BR0312664A (pt) | Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo | |
| Yu et al. | A model of tumor‐immune system interactions with healthy cells and immunotherapies | |
| Santos et al. | Radiation, pool size and incorporation studies in mice with 5-chloro-2′-deoxycytidine | |
| Sørensen | Gemcitabine in non-small cell lung cancer | |
| Heisig et al. | Durable remission of folliculotropic mycosis fungoides achieved with a combined topical treatment with cytarabine and carmustine | |
| Looney et al. | Solid tumor models for the assessment of different treatment modalities. XIII. Comparison of response and recovery of host and solid tumor to cyclophosphamide and radiation | |
| Chu et al. | Radiosensitizers and protectors | |
| Hill et al. | Therapeutic benefit from combined heat and radiation | |
| NO20001812D0 (no) | Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav | |
| Cortiana et al. | Immune Modulation in Sarcoma: Targeting the Tumor Microenvironment. | |
| Omer et al. | Optimal control analysis in the treatment of solid tumors using combined therapy | |
| Dvir | DIPG-40. LONG TERM SURVIVAL OF A 14 YEAR OLD GIRL WITH H3K27M MUTATED DIFFUSE MIDLINE GLIOMA FOLLOWING RADIOTHERAPY AND PROLONGED TUMOR TREATING FIELDS (TTFIELDS)-CASE REPORT | |
| O'Malley Jr et al. | Combination gene therapy for salivary gland cancer | |
| Jamal | E3 Ubiquitin Ligases and Their Therapeutic Applications in Cancers: Narrative Review | |
| Hampton et al. | Photodynamic therapy: computer modeling of diffusion and reaction phenomena | |
| BRPI0411567A (pt) | uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente | |
| Zhou et al. | DIPG-39. ONCOHISTONE H3. 3K27M-DRIVEN CREB5/ID1 AXIS DICTATES THE MALIGNANT CELL STATES OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1156827 Country of ref document: EP |